4.6 Article

American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer

期刊

THYROID
卷 22, 期 11, 页码 1104-1139

出版社

MARY ANN LIEBERT, INC
DOI: 10.1089/thy.2012.0302

关键词

-

资金

  1. Thyroid Cancer Survivors Association
  2. Joan Shey of the Light of Life Foundation
  3. Pfizer, Inc. (New York, NY)
  4. Eisei Inc. (Woodcliff Lake, NJ)
  5. Amgen Inc. (Thousand Oaks, CA)
  6. Genzyme Corp. (Cambridge, MA)
  7. Daiichi Sankyo, Inc. (Parsippany, NJ)
  8. Daiichi Sankyo
  9. Genzyme

向作者/读者索取更多资源

Background: Anaplastic thyroid cancer (ATC) is a rare but highly lethal form of thyroid cancer. Rapid evaluation and establishment of treatment goals are imperative for optimum patient management and require a multi-disciplinary team approach. Here we present guidelines for the management of ATC. The development of these guidelines was supported by the American Thyroid Association (ATA), which requested the authors, members the ATA Taskforce for ATC, to independently develop guidelines for ATC. Methods: Relevant literature was reviewed, including serial PubMed searches supplemented with additional articles. The quality and strength of recommendations were adapted from the Clinical Guidelines Committee of the American College of Physicians, which in turn was developed by the Grading of Recommendations Assessment, Development and Evaluation workshop. Results: The guidelines include the diagnosis, initial evaluation, establishment of treatment goals, approaches to locoregional disease (surgery, radiotherapy, systemic therapy, supportive care during active therapy), approaches to advanced/metastatic disease, palliative care options, surveillance and long-term monitoring, and ethical issues including end of life. The guidelines include 65 recommendations. Conclusions: These are the first comprehensive guidelines for ATC and provide recommendations for management of this extremely aggressive malignancy. Patients with stage IVA/IVB resectable disease have the best prognosis, particularly if a multimodal approach (surgery, radiation, systemic therapy) is used, and some stage IVB unresectable patients may respond to aggressive therapy. Patients with stage IVC disease should be considered for a clinical trial or hospice/palliative care, depending upon their preference.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据